We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Virus Linked to Breast Cancer Suggests a Vaccine

By Biotechdaily staff writers
Posted on 08 Jun 2004
A study has found evidence of a link between adult exposure to cytomegalovirus (CMV) and breast cancer in women under the age of 40, which suggests that a vaccine against the virus in childhood might be a way to decrease the risk of breast cancer. More...


The study involved 377 women, whose blood samples were tested for antibody levels to CMV and the Epstein-Barr virus. Researchers found that the women with breast cancer had higher CMV antibody levels than women without cancer. However, no link was found between the Epstein-Barr virus and breast cancer.

"The higher antibody levels could be the result of more recent infection with cytomegalovirus,” said principal researcher Dr. Ann Richardson. "This may mean that late infection with cytomegalovirus, rather than in childhood, is a risk factor for breast cancer.” It is not unusual to find links between viruses and increased cancer risk, noted Dr. Richardson. Several cancers, including cervical, liver, and some forms of leukemia are known to be caused by viruses. CMV is a common virus that is shed in breast milk as well as in saliva, urine, cervical secretions, and semen.

"Countries where most people are exposed to cytomegalovirus and other viruses in childhood have lower rates of breast cancer,” remarked Dr. Richardson. Further research is needed. If late infection with CMV is found to increase the risk of breast cancer, it might be possible to decrease the risk by exposing people to the virus by immunization in childhood.

The study was conducted by researchers at the University of Otago's Christchurch School of Medicine and Health Sciences and Dunedin School of Medicine (Dunedin, New Zealand), with colleagues from the University of Melbourne (Australia).



Related Links:
U.Otago's Christchurch School of Med.

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
Gold Member
Aspiration System
VACUSAFE
New
HPV Molecular Test
BD Onclarity HPV Assay
New
Japanese Encephalitis Test
Japanese Encephalitis Virus Real Time PCR Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.